Ebola Outbreak in DR Congo Reaches 600 Cases as Vaccine Development Could Take Nine Months
Kinshasa, 21 May 2026
The Democratic Republic of Congo faces its 17th Ebola outbreak with 600 suspected cases and 139 deaths, caused by the rare Bundibugyo strain not seen for over a decade. Unlike previous outbreaks, no approved vaccine exists for this strain, with WHO experts warning that developing effective protection could take up to nine months. The outbreak has spread to Uganda, with two confirmed cases in Kampala including one death. Medical facilities are overwhelmed, with aid workers reporting no space for new patients. The WHO declared a global health emergency on 17th May, though officials maintain the risk to Europe remains very low.
Rapid Escalation Since Emergency Declaration
Following the WHO’s declaration of a public health emergency of international concern on 17th May 2026, the outbreak has shown concerning momentum [1]. The WHO Emergency Committee convened in Geneva on Wednesday, 19th May 2026, as case numbers continued to climb [1]. Current figures reveal 51 confirmed cases across the Democratic Republic of Congo’s Ituri and North Kivu provinces, alongside Uganda’s two confirmed cases in Kampala, one of which proved fatal [2][3]. These confirmed infections represent only a fraction of the 600 suspected cases being monitored across the region [1][2]. The outbreak’s epicentre remains in Ituri province, where the first known case—a nurse who died on 24th April 2026 in Bunia—was initially identified [2][3].
International Response and European Risk Assessment
International health authorities have moved swiftly to contain potential spread beyond Central Africa. The United Kingdom announced up to £20 million in emergency funding to support containment efforts [2][3], whilst the United States has committed $13 million (£9.7 million) in emergency aid for both DR Congo and Uganda [6]. European Union officials sought to reassure the public on Wednesday, 19th May 2026, with spokesperson Eva Hrncirova stating that whilst ‘diseases do not stop at the borders’, the risk of an Ebola outbreak in Europe remains ‘very low’ [1]. This assessment aligns with WHO Director-General Tedros Adhanom Ghebreyesus’s evaluation that the epidemic poses a high risk at national and regional levels but remains low at the global level [1]. The cautious optimism extends to medical evacuation protocols, as demonstrated when a European medical missionary who contracted Ebola in the DRC was transported to Germany for treatment on 19th May 2026 [1].
Vaccine Development Challenges and Timeline
The absence of an approved vaccine for the Bundibugyo strain presents a significant challenge not encountered in recent Ebola responses. WHO advisor Dr Vasee Moorthy outlined the development timeline on Wednesday, 14th May 2026, explaining that two candidate vaccines are in development but neither has undergone clinical trials [2][3]. The most promising candidate, described as ‘the equivalent of’ the existing Zaire strain vaccine, could take six to nine months before becoming available [2]. A second vaccine candidate, based on the AstraZeneca platform, offers a potentially faster timeline with clinical trial doses possible within two to three months, pending successful animal trial results [2]. This extended development period contrasts sharply with previous outbreaks where existing vaccines provided immediate deployment options. The Bundibugyo strain, which previously caused outbreaks in Uganda in 2007 and DR Congo in 2012, kills approximately one-third of those infected [2][3].
Overwhelmed Healthcare Infrastructure and Community Impact
Healthcare facilities across the affected regions are struggling to cope with the surge in suspected cases. Trish Newport, emergency programme manager for Médecins Sans Frontières, reported that medical centres are ‘full of suspect cases’ with ‘no space’ for additional patients [2][3]. This capacity crisis unfolds against a backdrop of profound community anxiety, as local residents adapt their daily behaviours to reduce transmission risk. Araali Bagamba, a lecturer in Bunia, observed significant behavioural changes among the population: ‘For the last three days I haven’t shaken anyone’s hand and I observe that within the general population… It’s our habit to shake hands all the time… [but] the habit has changed’ [2]. The social impact extends beyond healthcare facilities, with a taxi driver from Rwampara expressing the community’s fear: ‘Ebola has tormented us… I am afraid because people are dying in large numbers… We are very afraid’ [6]. WHO emergencies chief Chikwe Ihekweazu emphasised that the ‘absolute priority now is to identify all the existing chains of transmission’ to properly define the outbreak’s scale and provide adequate care [1].